Cargando…
Preliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity
Fungi cause disease in nearly one billion individuals worldwide. Only three classes of antifungal agents are currently available in mainstream clinical use. Emerging and drug-resistant fungi, toxicity, and drug-drug interactions compromise their efficacy and applicability. Consequently, new and impr...
Autores principales: | Duncan, Vanessa, Smith, Daniel, Simpson, Laura, Lovie, Emma, Katvars, Laura, Berge, Leon, Robertson, Jennifer, Smith, Shane, Munro, Carol, Mercer, Derry, O’Neil, Deborah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284473/ https://www.ncbi.nlm.nih.gov/pubmed/34031048 http://dx.doi.org/10.1128/AAC.02345-20 |
Ejemplares similares
-
NP108, an Antimicrobial Polymer with Activity against Methicillin- and Mupirocin-Resistant Staphylococcus aureus
por: Mercer, Derry K., et al.
Publicado: (2017) -
Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate
por: Mercer, Derry K., et al.
Publicado: (2019) -
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
por: Fraser-Pitt, Douglas, et al.
Publicado: (2016) -
NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile
por: Mercer, Derry K, et al.
Publicado: (2020) -
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
por: Mercer, Derry K., et al.
Publicado: (2020)